Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 7.14
PACB's Cash to Debt is ranked higher than
67% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. PACB: 7.14 )
PACB' s 10-Year Cash to Debt Range
Min: 6.81   Max: No Debt
Current: 7.14

Equity to Asset 0.44
PACB's Equity to Asset is ranked higher than
60% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. PACB: 0.44 )
PACB' s 10-Year Equity to Asset Range
Min: -2.1   Max: 0.92
Current: 0.44

-2.1
0.92
F-Score: 5
Z-Score: -3.62
M-Score: -2.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -117.30
PACB's Operating margin (%) is ranked higher than
70% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. PACB: -117.30 )
PACB' s 10-Year Operating margin (%) Range
Min: -65237.04   Max: -275.16
Current: -117.3

-65237.04
-275.16
Net-margin (%) -121.95
PACB's Net-margin (%) is ranked higher than
70% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. PACB: -121.95 )
PACB' s 10-Year Net-margin (%) Range
Min: -64965.19   Max: -281.37
Current: -121.95

-64965.19
-281.37
ROE (%) -94.65
PACB's ROE (%) is ranked higher than
59% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. PACB: -94.65 )
PACB' s 10-Year ROE (%) Range
Min: -272.85   Max: -46.42
Current: -94.65

-272.85
-46.42
ROA (%) -47.37
PACB's ROA (%) is ranked higher than
64% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. PACB: -47.37 )
PACB' s 10-Year ROA (%) Range
Min: -81.89   Max: -41.75
Current: -47.37

-81.89
-41.75
ROC (Joel Greenblatt) (%) -717.72
PACB's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. PACB: -717.72 )
PACB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2466.26   Max: -529.13
Current: -717.72

-2466.26
-529.13
Revenue Growth (%) 38.30
PACB's Revenue Growth (%) is ranked higher than
95% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. PACB: 38.30 )
PACB' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 38.3
Current: 38.3

0
38.3
EBITDA Growth (%) -56.40
PACB's EBITDA Growth (%) is ranked higher than
52% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. PACB: -56.40 )
PACB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -56.4
Current: -56.4

EPS Growth (%) -55.30
PACB's EPS Growth (%) is ranked higher than
53% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. PACB: -55.30 )
PACB' s 10-Year EPS Growth (%) Range
Min: 0   Max: -55.3
Current: -55.3

» PACB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PACB Guru Trades in Q4 2013

Lee Ainslie 6,459,784 sh (+11.09%)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
» More
Q1 2014

PACB Guru Trades in Q1 2014

Steven Cohen 10,300 sh (New)
Jim Simons 105,766 sh (New)
Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
» More
Q2 2014

PACB Guru Trades in Q2 2014

Lee Ainslie 6,459,784 sh (unchged)
Murray Stahl 12,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

PACB Guru Trades in Q3 2014

Murray Stahl 12,000 sh (unchged)
Lee Ainslie 6,459,784 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PACB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2013-09-30 Add 64.63%0.17%$2.5 - $5.98 $ 7.06105%5814719
Jean-Marie Eveillard 2012-09-30 Sold Out 0.0013%$1.7 - $2.32 $ 7.06258%0
John Griffin 2012-06-30 Sold Out 0.05%$1.83 - $3.7 $ 7.06185%0
Jean-Marie Eveillard 2012-03-31 New Buy$2.94 - $5.04 $ 7.0690%150000
George Soros 2011-09-30 Sold Out 0.0018%$3.55 - $12.24 $ 7.06-11%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.41
PACB's P/B is ranked higher than
65% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. PACB: 9.41 )
PACB' s 10-Year P/B Range
Min: 0.52   Max: 9.41
Current: 9.41

0.52
9.41
P/S 9.29
PACB's P/S is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. PACB: 9.29 )
PACB' s 10-Year P/S Range
Min: 2   Max: 28.19
Current: 9.29

2
28.19
EV-to-EBIT -6.75
PACB's EV-to-EBIT is ranked lower than
54% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PACB: -6.75 )
PACB' s 10-Year EV-to-EBIT Range
Min: -6.7   Max: 0.5
Current: -6.75

-6.7
0.5
Current Ratio 3.92
PACB's Current Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. PACB: 3.92 )
PACB' s 10-Year Current Ratio Range
Min: 3.92   Max: 14.06
Current: 3.92

3.92
14.06
Quick Ratio 3.53
PACB's Quick Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. PACB: 3.53 )
PACB' s 10-Year Quick Ratio Range
Min: 3.53   Max: 13.74
Current: 3.53

3.53
13.74

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.41
PACB's Price/Net Cash is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. PACB: 16.41 )
PACB' s 10-Year Price/Net Cash Range
Min: 1.02   Max: 12
Current: 16.41

1.02
12
Price/Net Current Asset Value 13.07
PACB's Price/Net Current Asset Value is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. PACB: 13.07 )
PACB' s 10-Year Price/Net Current Asset Value Range
Min: 0.95   Max: 9.87
Current: 13.07

0.95
9.87
Price/Tangible Book 9.41
PACB's Price/Tangible Book is ranked higher than
72% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. PACB: 9.41 )
PACB' s 10-Year Price/Tangible Book Range
Min: 0.8   Max: 7.29
Current: 9.41

0.8
7.29
Price/Median PS Value 1.22
PACB's Price/Median PS Value is ranked higher than
83% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PACB: 1.22 )
PACB' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 3.56
Current: 1.22

0.39
3.56
Earnings Yield (Greenblatt) -14.80
PACB's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. PACB: -14.80 )
PACB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 188.2   Max: 26942.4
Current: -14.8

188.2
26942.4

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:P09.Germany
Pacific Biosciences of California, Inc., was incorporated in the State of Delaware in 2000. The Company develops, manufactures and markets an integrated platform for high resolution genetic analysis. It has developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, it created a technology platform using its proprietary single molecule, real-time, or SMRT, technology. Its SMRT technology uses the natural processing power of enzymes, combined with specially designed reagents and detection systems, to record individual biochemical events as they occur. The ability to observe single molecule events in real time provides the scientific community with an advanced tool for investigating basic biochemical processes such as DNA synthesis. Its SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. It has commercialized the PacBioRS II High Resolution Genetic Analyzer to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT) technology, its products enable scientists to increase their understanding of biological systems through targeted sequencing and insight into genetic variations. The Company's products include the SMRT Cell, Phospholinked nucleotides, the PacBio RS. Its competitors include Illumina Inc. and Thermo Fisher Scientific Inc. The names "Pacific Biosciences," "PacBio," "SMRT," "SMRTbell" and its logo are the trademarks of the Company. It is subject to federal, state, local and foreign laws, regulations and permits relating to environmental, health and safety matters.
» More Articles for PACB

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: CLR, CLMS, OPK, PACB, GAIN Dec 16 2013 
Weekly CEO Buys Highlight: OPK, PACB, CUBI, ARCP, RLYP Nov 25 2013 
Weekly CEO Buys Highlight: PHII, TUES, PACB, IPHI, WMC Dec 09 2012 
Weekly CEO Buys Highlight: PACB, AKS, EPIQ, GGS, TPGI Dec 02 2012 
Weekly CEO Buys Highlight: FFIN, STEC, MPO, PACB, TPGI Nov 25 2012 
Weekly CEO Buys Highlight: SUNS, PACB, GM, NPO, DGX Aug 11 2012 

More From Other Websites
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Financials Nov 14 2014
Researchers Use PacBio Sequencing to Create More Complete Human Genome Reference and Discover New... Nov 10 2014
Researchers Use PacBio Sequencing to Create More Complete Human Genome Reference and Discover New... Nov 10 2014
10-Q for Pacific Biosciences of California, Inc. Nov 07 2014
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 10-Q, Quarterly Report Nov 05 2014
Big Board Biotech Stocks in Play This Week Oct 28 2014
New DNA Sequencing Facility Established in China Based on PacBio's SMRT Sequencing Platform Oct 27 2014
New DNA Sequencing Facility Established in China Based on PacBio's SMRT Sequencing Platform Oct 27 2014
Edwards Lifesciences (EW) Worth Watching: Stock Up 11% Oct 27 2014
Edwards Lifesciences Tops Q3 Earnings, Revenues; Ups View Oct 24 2014
Pacific Biosciences posts 3Q loss Oct 23 2014
Pacific Biosciences posts 3Q loss Oct 23 2014
Pacific Biosciences Reports Third Quarter 2014 Financial Results Oct 23 2014
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Files SEC form 8-K, Results of Operations and Financial... Oct 23 2014
Pacific Biosciences Reports Third Quarter 2014 Financial Results Oct 23 2014
Q3 2014 Pacific Biosciences of California Inc Earnings Release - After Market Close Oct 23 2014
The Zacks Analyst Blog Highlights: Pacific Biosciences of California, Teva Pharmaceutical... Oct 22 2014
Should You Sell Pacific Biosciences of California (PACB) Before Earnings? Oct 22 2014
Can Pacific Biosciences Stock Continue to Grow Earnings? Oct 22 2014
Pacific Biosciences to Incur Narrower-than-Expected Q3 Loss Oct 21 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK